ESC 365 - Q&A - Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes.

HFA Premium Access

Q&A - Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes.

Session: Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes (EBAC Accredited)

Topic: Diabetes and the Heart

Speaker: Professor S. Verma (Toronto, CA) Professor M. Cowie (Cambridge, GB) Professor A. Mebazaa (Paris, FR) Professor M. Pfeffer (Boston, US)

Organised by the Sahlgrenska Academy, University of Gothenburg, Sweden, supported with an educational grant from AstraZeneca. Course Director: Professor Karl Swedberg

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speakers

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)

31 presentations

3 followers

Professor Martin Cowie

AstraZeneca, Cambridge (United Kingdom of Great Britain & Northern Ireland)

112 presentations

5 followers

Professor Alexandre Mebazaa

Hospital Lariboisiere, Paris (France)

82 presentations

21 followers

Professor Marc Pfeffer

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

27 presentations

1 follower

5 more presentations in this session

Welcome and introductions - Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes.

Speaker: Professor A. Mebazaa (Paris, FR)

Access

What have cardiovascular outcomes trials taught us about cardiovascular risk management?

Speaker: Professor M. Pfeffer (Boston, US)

Access

Emerging knowledge on cardiorenal protection.

Speaker: Professor S. Verma (Toronto, CA)

Access

From classroom to clinic: sodium–glucose co-transporter 2 inhibitor evidence in practice.

Speaker: Professor S. Verma (Toronto, CA) Professor M. Cowie (Cambridge, GB) Doctor S. Wiviott (Boston, US) Professor A. Mebazaa (Paris, FR)

Access

What we still need to learn from sodium–glucose co-transporter 2 inhibitors to predict the future.

Speaker: Professor M. Cowie (Cambridge, GB)

Access

Access the full session

Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes (EBAC Accredited)

Speakers: Professor S. Verma, Professor M. Cowie, Professor A. Mebazaa, Professor M. Pfeffer, Professor A. Mebazaa...

Access

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources